Extrait

Phase 1: To evaluate the toxicity profile of escalating doses of CO-1686 and to determine the MTD and RP2D To characterize the PK profile of CO-1686 Phase 2: To evaluate tumor response (ORR + duration of response) to CO-1686 in patients with T790M

Critère d'inclusion

• Previously treated NSCLC patients who have documented evidence of an activating mutation in the EGFR gene and have failed treatment with an EGFR inhibitor such as erlotinib or gefitinib

Liens

• ictrp
• euctr